Jeil Pharma Holdings Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Jeil Pharma Holdings.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 33.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23
Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jeil Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 778,787 | -41,476 | 7,925 | 15,717 | N/A |
| 6/30/2024 | 783,556 | -39,535 | -9,866 | -1,491 | N/A |
| 3/31/2024 | 785,871 | -26,016 | 2,285 | 10,665 | N/A |
| 12/31/2023 | 804,043 | -16,250 | -14,209 | -4,416 | N/A |
| 9/30/2023 | 790,514 | -61,754 | -35,195 | -22,119 | N/A |
| 6/30/2023 | 791,025 | -61,890 | -30,532 | -10,345 | N/A |
| 3/31/2023 | 805,169 | -62,525 | -55,203 | -32,518 | N/A |
| 12/31/2022 | 792,965 | -74,556 | -38,666 | -17,256 | N/A |
| 9/30/2022 | 788,177 | -9,373 | -35,875 | -13,605 | N/A |
| 6/30/2022 | 791,598 | -7,970 | -22,222 | -1,725 | N/A |
| 3/31/2022 | 771,045 | -6,572 | -3,797 | 16,229 | N/A |
| 12/31/2021 | 762,568 | -3,482 | -10,193 | 13,403 | N/A |
| 9/30/2021 | 767,983 | 6,564 | -4,992 | 17,832 | N/A |
| 6/30/2021 | 759,041 | 7,141 | -14,163 | 1,365 | N/A |
| 3/31/2021 | 759,246 | 8,169 | -33,524 | -20,993 | N/A |
| 12/31/2020 | 761,997 | 11,431 | -33,921 | -23,671 | N/A |
| 9/30/2020 | 757,246 | -88,013 | -65,846 | -24,665 | N/A |
| 6/30/2020 | 749,593 | -87,489 | -63,611 | -21,830 | N/A |
| 3/31/2020 | 741,802 | -87,956 | -34,212 | 6,760 | N/A |
| 12/31/2019 | 731,805 | -90,492 | -12,797 | 25,216 | N/A |
| 9/30/2019 | 641,560 | 8,346 | 13,849 | 16,216 | N/A |
| 6/30/2019 | 475,939 | 7,946 | 20,364 | 22,302 | N/A |
| 3/31/2019 | 306,884 | 7,314 | -41,803 | 8,791 | N/A |
| 12/31/2018 | 142,736 | 7,070 | -53,649 | -3,433 | N/A |
| 9/30/2018 | 64,032 | 110,929 | -49,321 | 384 | N/A |
| 6/30/2018 | 59,708 | 7,159 | N/A | -872 | N/A |
| 3/31/2018 | 53,134 | 5,289 | N/A | -5,534 | N/A |
| 12/31/2017 | 48,236 | 5,036 | N/A | 5,923 | N/A |
| 9/30/2017 | 43,657 | -102,540 | N/A | -831 | N/A |
| 6/30/2017 | 41,355 | 947 | N/A | -5,855 | N/A |
| 3/31/2017 | 40,824 | 1,610 | N/A | 16,420 | N/A |
| 12/31/2016 | 40,604 | 2,178 | N/A | 11,355 | N/A |
| 12/31/2015 | 594,716 | 9,761 | N/A | 2,743 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A002620's forecast earnings growth is above the savings rate (2.7%).
Earnings vs Market: Insufficient data to determine if A002620's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A002620's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A002620's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A002620's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A002620's Return on Equity is forecast to be high in 3 years time